Condition
Autoantibodies Screening
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Recruiting1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07364656Not ApplicableNot Yet Recruiting
Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors
NCT06665815Recruiting
A National Screening Program for Islet Autoantibodies Among First-degree Relatives of T1D Patients
Showing all 2 trials